Autistic children taking the drug showed improvements in some behaviors but not in their social skills.

This month’s issue of the Going on Trial newsletter explores why it’s more fun to have a beer with friends than by yourself — and how that informs an ongoing clinical trial for autism.

The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.

If a therapy for autism’s core traits makes it to market, it will likely take one of three forms, the researchers say.

The result raises hopes for an ongoing clinical trial in people — and offers fresh insight into the biology of imprinting and the UBE3A antisense transcript.

The changes may help explain the link between maternal infection and autism, though more research is needed.

Some conditions are too rare for conventional drug trials, leading some scientists to test bespoke treatments in single participants. Gleeson discusses the merits — and limitations — of these tiny trials.

This month’s issue of the Going on Trial newsletter examines personalized therapies for rare conditions, Acadia’s new drug for Rett syndrome and developments in a cord-blood program, among other autism-related drug trial news.

Studies of behavioral treatments for autism are complex and can easily be misunderstood. Here we provide some guidance.

Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.